Norway
· Delayed Price · Currency is NOK BerGenBio ASA Statistics
Total Valuation
BerGenBio ASA has a market cap or net worth of NOK 329.86 million. The enterprise value is 155.01 million.
| Market Cap | 329.86M |
| Enterprise Value | 155.01M |
Important Dates
The next estimated earnings date is Wednesday, February 26, 2025.
| Earnings Date | Feb 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BerGenBio ASA has 39.09 million shares outstanding. The number of shares has increased by 306.33% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 39.09M |
| Shares Change (YoY) | +306.33% |
| Shares Change (QoQ) | +8.97% |
| Owned by Insiders (%) | 6.28% |
| Owned by Institutions (%) | 7.50% |
| Float | 22.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.15 |
| P/TBV Ratio | 2.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.02 |
| EV / Sales | 297.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.71
| Current Ratio | 4.71 |
| Quick Ratio | 4.58 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -96.83% and return on invested capital (ROIC) is -64.06%.
| Return on Equity (ROE) | -96.83% |
| Return on Assets (ROA) | -52.67% |
| Return on Capital (ROIC) | -64.06% |
| Revenue Per Employee | 34,733 |
| Profits Per Employee | -10.15M |
| Employee Count | 16 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.53% in the last 52 weeks. The beta is 1.56, so BerGenBio ASA's price volatility has been higher than the market average.
| Beta (5Y) | 1.56 |
| 52-Week Price Change | -72.53% |
| 50-Day Moving Average | 8.99 |
| 200-Day Moving Average | 11.19 |
| Relative Strength Index (RSI) | 43.49 |
| Average Volume (20 Days) | 232,007 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BerGenBio ASA had revenue of NOK 521,000 and -152.29 million in losses. Loss per share was -4.74.
| Revenue | 521,000 |
| Gross Profit | 521,000 |
| Operating Income | -161.26M |
| Pretax Income | -152.29M |
| Net Income | -152.29M |
| EBITDA | -161.04M |
| EBIT | -161.26M |
| Loss Per Share | -4.74 |
Balance Sheet
| Cash & Cash Equivalents | 174.84M |
| Total Debt | n/a |
| Net Cash | 174.84M |
| Net Cash Per Share | 4.47 |
| Equity (Book Value) | 153.38M |
| Book Value Per Share | 3.92 |
| Working Capital | 153.27M |
Cash Flow
| Operating Cash Flow | -138.99M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -30,951.06% |
| Pretax Margin | -29,230.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BerGenBio ASA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -306.33% |
| Shareholder Yield | -306.33% |
| Earnings Yield | -56.18% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 0.01.
| Last Split Date | May 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
BerGenBio ASA has an Altman Z-Score of 6.18.
| Altman Z-Score | 6.18 |
| Piotroski F-Score | n/a |